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The small neuroendocrineprotein 7B2 is required for thepro-
duction of active prohormone convertase 2 (PC2), an enzyme
involved in the synthesis of peptide hormones, such as glucagon
and proopiomelanocortin-derived -melanocyte-stimulating
hormone. However, whether 7B2 can dynamically modulate
peptide production through regulation of PC2 activity
remains unclear. Infection of the pancreatic alpha cell line
-TC6 with 7B2-encoding adenovirus efficiently increased
production of glucagon, whereas siRNA-mediated knock-
down of 7B2 significantly decreased stored glucagon. Fur-
thermore, rescue of 7B2 expression in primary pituitary
cultures prepared from 7B2 null mice restored melanocyte-
stimulating hormone production, substantiating the role of
7B2 as a regulatory factor in peptide biosynthesis. In anterior
pituitary and pancreatic beta cell lines, however, overexpres-
sion of 7B2 affected neither production nor secretion of pep-
tides despite increased release of active PC2. In direct con-
trast, 7B2 overexpression decreased the secretion and
increased the activity of PC2 within -TC6 cells; the
increased intracellular concentration of active PC2 within
these cells may therefore account for the enhanced produc-
tion of glucagon. In line with these findings, we found ele-
vated circulating glucagon levels in 7B2-overexpressing cast/
cast mice in vivo. Surprisingly, when proopiomelanocortin
and proglucagon were co-expressed in either pituitary or
pancreatic alpha cell lines, proglucagon processing was pref-
erentially decreased when 7B2 was knocked down. Taken
together, these results suggest that proglucagon cleavage has
a greater dependence on PC2 activity than other precursors
and moreover that 7B2-dependent routing of PC2 to secre-
tory granules is cell line-specific. The manipulation of 7B2
could therefore represent an effective way to selectively reg-
ulate synthesis of certain PC2-dependent peptides.
Prohormone convertase 2 (PC2)3 belongs to the family of
subtilisin-related proteolytic enzymes thought to mediate the
majority of proteolytic cleavages of peptide hormone precur-
sors (1–4). For example, during themultistep processing of the
peptide precursor proopiomelanocortin (POMC), PC2 acts to
cleave intact adrenocorticotropic hormone 1–39 (ACTH) into
adrenocorticotropic hormone 1–14, the precursor to -mela-
nocyte-stimulating hormone (-MSH). PC2 is also thought to
be involved in the synthesis of -endorphin and glucagon
(4–6). The neuroendocrine protein 7B2, discovered in 1982
(7), facilitates the maturation of proPC2 and is absolutely
required for expression of this convertase’s enzymatic activity
(8–12) (reviewed in Refs. 13 and 14). 7B2 accomplishes this by
blocking the unproductive aggregation of the PC2 precursor
into unactivatable aggregates (15). 7B2 itself is proteolytically
cleaved from a larger form, 27-kDa 7B2, to its bioactive 21-kDa
form by removal of a C-terminal domain. This removal ismedi-
ated by furin or a furin-like convertase within the trans-Golgi
network (16). The amino-terminal 21-kDa domain is responsi-
ble for chaperoning the proPC2 maturation process (reviewed
in Ref. 17).
Mice null for the 7B2 protein are unable to generate active
pituitary prohormone convertase 2 (18). In thesemice, the nor-
mal PC2-mediated process of internal cleavage of adrenocorti-
cotropic hormone 1–39 does not occur in the intermediate
lobe, despite the presence of ample quantities of proPC2 (18).
Hypersecretion of adrenocorticotropic hormone 1–39 into the
circulation ensues, which leads to adrenocortical stimulation,
highly increased circulating corticosterone, and ultimately to
numerous pathologies as a consequence of severe disturbance
in the pituitary-adrenal axis (18–20). We have shown previ-
ously that administration of an adenoviral vector encoding 7B2
to 7B2 nullmice results in a significant decrease in pituitary and
circulating PC2 substrate adrenocorticotropic hormone 1–39
(21). Decreased adrenocorticotropic hormone is accompanied
by decreased circulating corticosterone and increased circulat-
ing-MSH.Oddly, however, overexpression of 7B2 in the adre-
nocorticotropic cell line AtT-20/PC2 does not increase cellular
production of -MSH (12).
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Recently, Schmidt et al. (22) reported that various strains of
mice expressing different levels of 7B2 exhibited circulating
glucagon levels that correlated with cellular 7B2 but not with
PC2 levels, strongly suggesting that 7B2 is rate-limiting for glu-
cagon production. However, cellular production of glucagon
was not systematically examined under conditions of 7B2 defi-
ciency and surplus. In order to determine whether 7B2 levels
can indeed dynamically modulate peptide production, we have
investigated the role of over- and underexpression of 7B2 in
various cell types and with different PC2-dependent
precursors.
EXPERIMENTAL PROCEDURES
Preparation of Recombinant Adenovirus—Recombinant
adenoviruses encoding either 27-kDa 7B2 or -galactosidase
(as a control) were initially made byM. Castro and S.Windeatt
and have been described previously by Sarac et al. (21). Viral
stocks were assayed for the presence of replication-competent
adenovirus using a replication competency assay by the super-
natant rescue assay (23). The presence of endotoxin was also
assayed (21). 911 cells were used for routine purification of
adenoviruses. Double cesium chloride gradient centrifugation
was performed on cell extracts using a Beckman SW41 rotor for
2 h (for the first centrifugation) and for 18 h (for the second
centrifugation) at 24,000 g at 4 °C. After isolation of the viral
band, cesium chloride was removed using Sepharose CL-4B
spin columns. The adenoviral particles were stored in 5%
sucrose in virus storage buffer (150mMNaCl, 20mMHepes, pH
7.8) at 70 °C (21). For some experiments, viruses were pre-
pared by LSUHSC Vector Core Laboratories at similar titers
and purity.
Cell Culture—Pituitary primary cell cultures were generated
from 7B2 null mice sacrificed by decapitation. Pituitaries were
removed from the sella turcica; two pituitaries per tube were
placed in a 15-ml conical tube with Earle’s medium containing
1% BSA (fatty acid-free) and 25mMHepes, pH 7.4. Collagenase
solution, containing 4 mg/ml type IV collagenase (Sigma), 1
mg/ml hyaluronidase (Sigma), 0.01 mg/ml DNase I (Sigma),
and 10 mg/ml fatty acid-free BSA (Roche Applied Science) in
DMEMhigh glucose (4.5 g/liter D-glucose, catalogue no. 11995,
Invitrogen), was added. Tissues were incubated for 5 min at
37 °C with shaking to dissociate the gland. Tissue fragments
were collected by centrifugation for 5min at 24,000 g at room
temperature; the supernatant was carefully removed and dis-
carded. The tissues were then resuspended in 5 ml/tube of 3
mg/ml trypsin in DMEM. Resuspended tissues were incubated
for 5 min at 37 °C and then centrifuged. The pellet was resus-
pended in 5 ml/tube of 1 mg/ml lima bean trypsin inhibitor
(Sigma) in DMEM high glucose solution in order to neutralize
trypsin. Cells were then washed with 3 ml of plating medium
containing high glucose DMEM, 10% fetal bovine serum (FBS;
Irvine Scientific, Santa Ana, CA), and 0.5% gentamycin. Cells
were plated into 24-well plates in 1.5 ml/well plating medium
and incubated at 37 °C/5% CO2. After 24 h of incubation, the
medium was replaced with 2 ml of fresh plating medium. We
used 2-day-old primary pituitary cell cultures for all
experiments.
AtT-20 cells were obtained from the American Tissue Type
Collection, whereas AtT-20/PC2 cells were obtained from Dr.
Richard Mains (3). Both cell lines were cultured in DMEM
(Invitrogen) containing 10% Nuserum (BD Biosciences), 2.5%
FBS, and G418 (0.3 mg/ml) was added to AtT-20/PC2 cells to
maintain PC2 expression. All cells were split into 6-well plates
at 0.3 106 cells/well. After 24 h, one well of cells was counted
to calculate the appropriate adenoviral vector titer. RinPE cells
represent a stable rat insulinoma cell line originally derived
from Rin5f and stably transfected with rat proenkephalin (24);
these cells were maintained in DMEM containing 1 g/liter glu-
cose (Invitrogen), 10% FBS, G418 (0.3 mg/ml); -TC6 cells, a
mouse alpha cell line, were grown in DMEM containing 1 g/li-
ter D-glucose, 5% FBS, 15% horse serum (Irvine Scientific), and
penicillin/streptomycin (100 units/g/ml; Invitrogen).
Adenoviral Infection of Primary Cultures—Each adenoviral
preparation was diluted to 5 106 plaque-forming units (pfu)/
well for pituitary primary cell cultures at a multiplicity of infec-
tion of 1. Each well was washed twice with PBS and infected
with diluted recombinant adenoviral vector. After incubation
for 30 min at room temperature, 2 ml of the growth medium
were added to each well, and cells were then incubated for 24 h
at 37 °C/5% CO2.
Adenoviral Infection of Cell Lines—To infect adenovirus into
cells, AtT-20/PC2, -TC6, and/or RinPE cells were split into
6-well plates at 106 cells/well and 0.3  106 cells/well, respec-
tively. Replicate wells were counted again the following day for
calculation of adenoviral multiplicity of infection. Cells were
washed twice with PBS, and adenovirus was diluted to achieve a
multiplicity of infection 1 (for AtT-20/PC2 and -TC6 cells)
or 3 (for RinPE cells) in PBS in a final volume of 1 ml/well. The
diluted adenovirus solution was added directly to cells in
growth medium, and the plates were swirled to mix well. The
plateswere incubated for 30min to permit adenoviral infection.
Two ml of DMEM containing high glucose and 2% FBS for
AtT-20/PC2 cells and DMEM containing low glucose and 2%
FBS for RinPE cells were then added to each well. Adenovirus-
infected cells were incubated for 36 h at 37 °C in a CO2 incuba-
tor. The medium was then changed overnight to Opti-MEM
(Invitrogen) containing 0.1 mg/ml aprotinin for PC2 assays;
alternatively, cells were used for metabolic labeling with
[35S]Met/Cys (AmershamBiosciences). Transfection efficiency
was tested in simultaneous experiments by visualizing trans-
fected cells using a -galactosidase-encoding control adenovi-
rus at the same concentration.
RNAi Experiments—Three different specific sequences of
stealth siRNA (Invitrogen) were designed for the murine 7B2
mRNA sequence (MSS237887, MSS237888, and MSS237889).
Following assessment of individual knockdown efficiencies, the
most effective siRNA, MSS237887, was deployed in all experi-
ments described here. A control scrambled sequence was
designed to have the same GC content (46-2000, Invitrogen).
Transfection efficiency in -TC6 cells wasmonitored and visu-
alized using a scrambled siRNA sequence conjugated to fluo-
rescein (N2100S, New England Biolabs (Ipswich, MA)). The
total cell number was determined by counterstaining with 5
g/ml Hoechst 33342 (Invitrogen) for 45 min and subsequent
examination by fluorescence microscopy. AtT-20/PC2 and
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-TC6 cells grown in 6-well plates were transfected sequen-
tially with a 100 nM concentration of the respective siRNA on
the first day and 200 nM on the second day using 5 l/well
Lipofectamine 2000 (Invitrogen).
Metabolic Labeling and Immunoprecipitation—After a 24-h
infection with adenoviruses encoding either 27-kDa 7B2 or
-galactosidase control adenovirus, AtT-20/PC2 and RinPE
cells were labeled with [35S]Met/Cys Promix for 20 min in
DMEM Met/Cys-free medium (ICN) and chased for 2 h in
DMEM high glucose medium and 2% fetal bovine serum at
37 °C. The chase medium and cell extracts were immunopre-
cipitated using either PC1/3 antiserum (2B6), PC2 antiserum
(18B8), or 7B2 antiserum (13B6), as described previously (7).
Triplicate samples (wells) of immunoprecipitated proteins
were separated by SDS-PAGE and visualized using a Storm 840
PhosphorImager (Amersham Biosciences). The density of
bands was determined using an Alpha Imager 3000 system
(Alpha Innotech Corp., San Leandro, CA). The expression lev-
els of 7B2, PC1/3, and PC2were calculated as integrated density
of bands (arbitrary units 105) and converted to percentages
of non-treated controls (n 3/group; data not shown).
Labeled proenkephalin present in RinPE cells was immuno-
precipitated using antiserum directed against its C-terminal
heptapeptide (Tyr-Gly-Gly-Arg-Phe) and analyzed at different
chase times following separation by high pressure gel perme-
ation chromatography, as described previously (24). Online
scintillation spectroscopy was used to follow labeled methio-
nine present in the various cleavage products.
Pituitary primary cell cultures were washed with PBS after
adenoviral infection for 24 h and then labeled with 0.5 mCi/ml
35S-labeled methionine and cysteine (Met/Cys) Promix in
methionine-free medium for 20 min and chased for 2 h in
medium containing cold methionine. After adenoviral infec-
tion, AtT-20/PC2 cells were incubated for 36 h, washed with
PBS, and then labeled as described above. Cell extracts and
conditionedmedia were then immunoprecipitated using either
PC2 or 7B2 antisera.
AtT-20 cells overexpressing PC2 were first transfected in
12-well plates with 250 l of DMEM containing 250 pM 7B2
siRNA (MSS237887) or 5 nM dsRNA using Lipofectamine 2000
(Invitrogen) and then incubated for 24 h at 37 °C. The cells were
further co-transfected with the same concentration of 7B2
siRNA (or control dsRNA) and 1 g of plasmid encoding
human preproglucagon (pTT-proglucagon, a kind gift of Five-
Prime Therapeutics, Inc.). Accordingly, -TC6 cells were co-
transfected with 2g of plasmid encoding POMC. After 24 h of
incubation, the transfected cells were labeled with 0.25 mCi of
35S-labeled methionine and cysteine, Transmix (MP Biomedi-
cals, Solon, OH) in RPMI-1680, methionine- and cysteine-free
medium (Invitrogen) for 20 min and chased for appropriate
time periods in Opti-MEM (Invitrogen) containing 0.1 mg/ml
aprotinin. Labeled proteins were extracted with 1 M acetic acid
and clarified by centrifugation. The cell extracts were lyophi-
lized and reconstituted with immunoprecipitation buffer con-
taining 100mMsodiumphosphate buffer, pH7.4, 150mMNaCl,
0.1% Triton X-100, and 0.5% Nonidet P-40. One-third of the
reconstituted cell extract was reserved in order to perform
radioimmunoassays to measure cellular -MSH and glucagon.
Immunoprecipitations of clarified extracts were performed
using either LS-41 antiserum (for POMC and POMC-derived
products (25)) or glucagon antiserum (Takara Bio, Inc., Otsu
Shiga, Japan) and protein A beads (GE Healthcare). Immuno-
precipitates were subjected to separation by high performance
gel permeation chromatography, as described previously (24),
and scintillation counting of fractions was performed using a
Beckman C5580 scintillation counter (Beckman Coulter, Brea,
CA).
Secretion Experiments and Radioimmunoassays—Twenty-
four h after infection, wells were washed twice with Opti-MEM
and incubated with 1 ml of Opti-MEM containing 0.1 mg/ml
aprotinin and BSA (5 g/ml) for 1 h at 37 °C. The medium was
replaced with 1 ml of Opti-MEM containing 0.1 mg/ml apro-
tinin and BSA (5 g/ml) for 2 h at 37 °C and then collected. For
stimulation experiments, 1 ml of Opti-MEM containing 100
g/ml aprotinin, BSA (5 g/ml), and 5 mM BaCl2 was added to
each well and then incubated for 1 h at 37 °C; in some experi-
ments, RPMI 1640 was used instead of Opti-MEM containing
0.1 mg/ml aprotinin. After the conditioned media were col-
lected, cells were homogenized immediately in 1ml of acid mix
(5 N acetic acid and 2mg/ml BSA). The homogenized cells were
frozen and then thawed and centrifuged. The supernatant was
lyophilized and resuspended in 500 l of RIA buffer (50 mM
sodium phosphate, pH 7.6, 0.1% Triton X-100, and 0.02%
sodium azide).
For -MSH assays, 5l of cell extracts, 50l (for basal secre-
tion) or 25 l (stimulated secretion) of medium samples from
pituitary primary cell cultures were subjected to assay in dupli-
cate using the -MSH RIA kit (Phoenix Pharmaceuticals, Bur-
lingame, CA). This anti--MSH-antiserum does not recognize
ACTH. For-MSH assays using cell extracts andmedium sam-
ples obtained from-TC6 andAtT-20/PC2 cells, the polyclonal
anti--MSH antiserum was commercially purchased from
Chemicon (Temecula, CA). Two m of cell extracts, 25 l (for
basal secretion) or 5 l (stimulated secretion) of medium sam-
ples were subjected to assay in duplicate. 125I-Labeled -MSH
was prepared by the chloramine-Tmethod originally described
by Hunter and Greenwood (26). RIA was carried out according
to protocols described previously (27). Samples were incubated
with 10,000 cpm of iodinated peptide and the appropriate dilu-
tion of rabbit antiserum in a final volume of 300 l at 4 °C
overnight. To separate the antibody-bound labeled peptide
from the unbound labeled peptide, 1 ml of 25% polyethylene
glycol and 100 l of 7.5% carrier bovine -globulin (in PBS)
were added. The samples were vortexed, kept on ice for 30min,
and then centrifuged for 20 min at 3,000  g at 4 °C using a
Sorvall RT6000B refrigerated centrifuge. The supernatant was
aspirated, and the radioactivity in the pellets was determined.
For ACTH assays, 5 l of a 1:20 dilution of cell extracts, 5 l
(for basal secretion) or 2 l (stimulated secretion) of medium
samples from pituitary primary cell cultures were subjected to
assay in duplicate using the two-site Nichols human ACTH
1–39 assay kit (Nichols Institute, San JuanCapistrano, CA). For
AtT-20/PC2 cells, 2 l of cell extracts, 25 l (for basal medium
samples) or 5l (stimulatedmedium samples) ofmedium sam-
ples were assayed. The 125I-ACTH antibody used in this kit is
directed to both N-terminal and C-terminal regions of intact
7B2Over- and Underexpression and Peptide Precursor Cleavage
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ACTHmolecule and does not recognize ACTH cleavage prod-
ucts. Radioactivity was determined using aWallac 1470Wizard
-counter (PerkinElmer Life Sciences).
For glucagon assays, 48 h after transfection with the respec-
tive siRNA, each well was washed twice with PBS (pH 7.4). The
PBS was replaced with 1 ml of 0.1 M HCl, and cells were col-
lected by scraping, frozen on dry ice, thawed, and centrifuged.
The supernatant was lyophilized and resuspended in 500 l of
RIA buffer (50 mM sodium phosphate, pH 7.6, 0.1% Triton
X-100, and 0.02% sodium azide) and centrifuged again. Ten l
of clarified -TC6 cell extract (7B2 RNAi-treated and scram-
bled controls) were subjected to assay in duplicate using a com-
mercially available glucagon RIA kit (GL-32K, EMDMillipore,
Billerica, MA). The anti-glucagon antiserum utilized in this kit
recognizes processed glucagon but not its precursor progluca-
gon or oxyntomodulin. Samples were assayed using the RIA
protocol according to the manufacturer’s instructions. Radio-
activity was determined using aWallac 1470Wizard -counter.
Enzyme Assays—After adenoviral infection of cell cultures
for 24 h, the medium was changed to 1 ml of Opti-MEM con-
taining 0.1 mg/ml aprotinin, and cells were allowed to secrete
for 18 h. The assay for PC2 in this conditioned medium was
carried out in 96-well polypropylene microtiter plates using 25
l of each conditioned medium sample in a total volume of 50
l, containing 200M fluorogenic substrate, Pyr-Arg-Thr-Lys-
Arg-methylcoumarinamide (Peptides International, Louisville,
KY), and 100mM sodium acetate, pH 5.0, 5mMCaCl2, and 0.1%
Brij 35, in the presence of a protease inhibitor mixture com-
posed of 1 M pepstatin, 0.28 mM tosylphenylalanyl chlorom-
ethyl ketone, 1 M trans-epoxysuccinic acid (E-64), and 0.14
mM tosyllysyl chloromethyl ketone. The rate of released 7-ami-
no-4-methylcoumarin was measured with a Fluoroscan Ascent
fluorometer (MTX Lab Systems, Inc., Vienna, VA) using an
excitationwavelength of 380 nmand an emissionwavelength of
460 nm for 1 h at 37 °C. Inhibition by the 7B2 C-terminal pep-
tide was used to assess specificity as described previously (28).
Animals—Intercrosses (B62D-3 F2) of the subcongenic
inbred strain (B62D-3, B6.CAST-(D2Mit329-D2Mit457)) were
maintained at the University of California (Davis, CA). 7B2 is
differentially expressed in these congenic mice, with relatively
low mRNA and protein levels in the b6/b6 genotype (consid-
ered as normal expressers), whereas cast/castmice are high 7B2
expressers with levels increased 2.5-fold over normal (29).
Expression of 7B2 in heterozygous b6/castmice is intermediate.
Samples of blood plasma were taken from male B62D-3 F2
mice, and glucagon levels in 100l of blood plasma were quan-
tified by RIA, as described above (b6/b6, n 8; b6/cast, n 3;
cast/cast, n 8). Blood glucose levels were measured in dupli-
cate using the same blood plasma samples using a handheld
glucose meter (Freestyle mini, Abbott (Abbott Park, IL)). All
animal protocols were managed according to the guidelines of
the AmericanAssociation for Accreditation of Laboratory Ani-
mal Care (AAALAC).
Statistical Analysis—Data were analyzed with one- or two-
wayANOVA followed by the Student-Newman-Keulsmultiple
comparison test, as appropriate, using a statistical software
package (SigmaStat, Systat Software, Inc. (San Jose, CA)).
Where data failed equal variance or normality tests, they were
analyzed with one-way ANOVA followed by Dunn’s multiple
comparison test. A probability value of p 0.05was considered
as statistically significant.
RESULTS
7B2 Adenoviral Infection Increases ACTH Processing to
-MSH in Primary Pituitary Cultures Prepared from 7B2 Null
Mice—Primary cell cultures derived frompituitaries of 7B2 null
mice were infected with either -galactosidase-encoding con-
trol virus or 27-kDa 7B2-encoding virus, respectively, labeled
with radioactivemethionine/cysteine; cell extracts were immu-
noprecipitated using antisera against PC2 and 7B2. 7B2 expres-
FIGURE 1. Infection of primary cultures of 7B2 null pituitaries with 7B2-
encoding adenovirus results in efficient expression of 7B2 but does not
affect proPC2 processing. Primary pituitary cell cultures derived from 7B2
null mice were infected with either (control) -galactosidase- or 7B2-encod-
ing adenovirus at 0.5 106 pfu/well in 12-well plates and subjected to met-
abolic labeling experiments as described under “Experimental Procedures.”
Cells were extracted with boiling immunoprecipitation buffer. Cell extracts
were immunoprecipitated using antisera against 7B2 (left) or PC2 (right)
under denaturing conditions. Although adenoviral transfection of pituitary
cells with a 7B2-expressing vector induced an efficient expression of 7B2, no
effect on the conversion of proPC2 to PC2was detected in these cells. C, con-
trol; 7B2-AV, 7B2 adenovirus.
FIGURE 2. Infection of primary cultures of 7B2 null pituitaries by 7B2-
encodingadenovirus increases stored-MSH levelsanddecreasesACTH
levels. Primary pituitary cell cultures derived from pituitaries of 7B2 nulls
were infected with -galactosidase (Control)- and 7B2-expressing adenoviral
vectors with 0.5 106 pfu/well in 12-well plates for 24 h. Acid extracts were
lyophilized and then resuspended in RIA buffer and subjected to radioimmu-
noassay for determination of -MSH (A) or ACTH levels (B). Expression of 7B2
was accompanied by an increase in cellular-MSH and a drop in ACTH levels.
Levels of secreted -MSH and ACTH in the medium were very low, and no
differences between 7B2 expressing and non-expressing cells were detecta-
ble. 7B2-AV, 7B2 adenovirus. Data represent n 3 wells/group, mean S.D.
(error bars).
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sion was robust in the primary cell cultures transfected with
7B2-encoding virus (Fig. 1, left). Despite the fact that stable
overexpression of 7B2 enhanced proPC2 processing to 68-kDa
PC2 in AtT-20 cells (12), cleavage of proPC2 still occurred effi-
ciently in primary cell cultures in the absence of 7B2, possibly
by other convertases (30) (Fig. 1, right).
7B2 overexpression resulted in increased cellular levels of
-MSH (Fig. 2A) and decreased levels of ACTH (Fig. 2B),
whereas concentrations of both peptides were very low in the
medium. These results indicate that overexpression of 7B2
increases POMC processing in primary cultures of 7B2 null
pituitary, similar to its effect in the intact animal (18).
7B2 Adenoviral Infection Enhances proPC2 Secretion and
Increases Secretion of Active PC2 in AtT-20/PC2 and RinPE
Cells—In order to determine whether 7B2 overexpression can
affect POMC processing and secretion in neuroendocrine cell
lines, we infected 7B2-encoding adenovirus into AtT-20/PC2
cells (these cells represent a PC2-transfected AtT-20 cell line
known to process the endogenous substrate, POMC, at PC2
cleavage sites (31)) and RinPE cells (a rat insulinoma cell line
stably overexpressing rat proenkephalin (24)). 35S labeling of
AtT-20/PC2 cells showed that 7B2was indeedwell expressed in
these cells (Fig. 3A, left). Adenoviral 7B2 overexpression did not
affect proPC2 processing into PC2 in cells infected with 7B2
FIGURE 3. Infectionof different endocrine cell lineswith 7B2-encoding adenovirus selectively increases the secretion andactivity of proPC2/PC2, but
not PC1/3, in RinPE cells. AtT-20/PC2 cells and RinPE cells were infected with 10 pfu/cell and 3 pfu/cell of either control or 7B2-encoding adenovirus,
respectively. Twenty-four h after infection, cells and media were subjected to metabolic labeling and enzyme activity experiments as described under
“Experimental Procedures.” A, cell extracts of AtT-20/PC2 cells were immunoprecipitated using antisera against either 7B2 (left) and PC2 (right) under dena-
turing conditions.Graphs below the representative blots showquantification of protein levels after normalization to protein content in control groups (n 3).
Overexpression of 7B2 in AtT-20/PC2 cells induced an increase of proPC2 and PC2 in themedium, but no differencewithin cells was observed. B, the increased
secretion of PC2 was accompanied by an increase in enzyme activity in the medium as determined by PC2 enzyme assay of conditioned medium. C–E,
metabolic labeling and immunoprecipitation demonstrates enhanced secretion of PC2 andproPC2 (C) but not PC1/3 (E) in themediumof 7B2-overexpressing
RinPE cells under basal and stimulated secretory conditions. The enhanced PC2 release in these cells was also reflected by an increase in PC2 activity in the
medium (D). 7B2-AV, 7B2 adenovirus;C, control adenovirus;N, normalwithout adenovirus. Data representn 3wells/group,mean S.D. (error bars); one-way
ANOVA; **, p 0.01.
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adenovirus (Fig. 3A, right). Secretion of proPC2 and PC2 from
AtT-20/PC2 cells was, however, slightly increased after adeno-
viral transfection with 7B2. Fig. 3B shows that the 7B2-en-
hanced release of proPC2/PC2 from AtT-20/PC2 cells is
reflected in a large increase in the release of PC2 activity. In
RinPE cells, adenoviral 7B2 overexpression also increased
secretion of radiolabeled proPC2 and PC2 into the medium;
this increase in secretion was observed when secretion was
either non-induced or stimulated by BaCl2 (Fig. 3C). The
increase of PC2 secretion in RIN-PE cells was accompanied by
an increase of PC2 activity in the medium (Fig. 3D). In contrast
to the observed changes in proPC2 and PC2 secretion, the
secretion of radiolabeled PC1/3 was not altered by the intro-
duction of 7B2 adenovirus into RinPE cells (Fig. 3E).
The relative abundance of endogenous 7B2 within the vari-
ous cell lines used (prior to adenovirus- or RNAi-mediated
manipulation of 7B2 levels) was comparable, as determined by
radioimmunoassay, with levels ranging from 25 to 35 fmol/100
l assayed sample (one-tenth of the total of a 6-well plate) (sup-
plemental Fig. S1). This observation is in line with Northern
blot analysis in a previous study that detected comparable 7B2
levels in these same cell lines (32).
In AtT-20/PC2 Cells and RinPE Cells, 7B2 Adenoviral Infection
Increases Secretion of Active PC2 but Does Not Enhance Precursor
Processing—Despite this increase in secreted PC2 activity, no sig-
nificant increase in either cellular, basal, or stimulation-dependent
secreted -MSH was detected (Fig. 4A, top); nor was there a
change in cellular or secretedACTH inAtT-20/PC2 cells (Fig. 4A,
bottom). Application of 7B2 siRNA to AtT-20/PC2 cultures also
failed to reduce cellular -MSH levels (Fig. 4B).
Adenoviral infection experiments were also performed in
RinPE cells. Fig. 3C shows that adenoviral 7B2overexpression also
enhanced the release of PC2 activity in this cell line. In metabolic
labeling studies, no alteration in the processing of proenkephalin
to the heptapeptide Met-enkephalin-Arg-Phe, a PC2-mediated
process (24),was evident followingoverexpressionof 7B2 (supple-
mental Fig. S2) despite thepresenceof amplequantities of thePC2
substrate Peptide B. These results show that in AtT-20/PC2 and
RinPE cells, 7B2 overexpression generates large increases in
secretedPC2activity, but this influencesneither cellularprecursor
processing nor the releasability of stored peptides.
In -TC6 Cells, Modulation of 7B2 Levels by Adenoviral
Infection or by siRNA Transfection Alters the Production of
Glucagon—A previous report using mouse strains expressing
different 7B2 levels had suggested that glucagon levels were
FIGURE 4. Manipulation of 7B2 levels in AtT-20/PC2 cells by adenoviral
infectionor antisensedoes not alter POMCprocessingor enhance secre-
tion of-MSH or ACTH. A, neither secreted nor intracellular levels of -MSH
or ACTH change following 7B2 overexpression. AtT-20/PC2 cells were
infected for 24 h with control adenovirus encoding either -galactosidase or
7B2. Following a 40-min basal collection period, cells were incubated in
medium containing 5mMBaCl2 for 40min to assess stimulated secretion. Cell
extracts and medium samples were assayed for -MSH and ACTH. Data are
presented as a percentage of total peptide (n  3 wells/group). BL, peptide
released under basal conditions; Stim, peptide released during BaCl2 stimula-
tion; Cells, peptide present in cells. B, RNAi-mediated knockdown of 7B2 does
not alter intracellular content of-MSH. AtT-20/PC2 cellswere transfected for
48 hwith either scrambled control siRNA or 7B2 siRNA, and cell extracts were
assayed for -MSH. Data represent n  3 wells/group, mean  S.D. (error
bars).
FIGURE 5. 7B2 adenoviral infection of -TC6 cells enhances the produc-
tionof cellularglucagon,whereas transfectionwith7B2antisense siRNA
lowers glucagon levels. -TC6 cells were infected for 24 h with control ade-
novirus encoding either -galactosidase (Gal/control) or 7B2 (7B2-AV). 7B2
overexpression by adenoviral infection in-TC6 cells increases 7B2 levels (A).
7B2-AV transfection efficiency was determined using a -Gal-encoding ade-
novirus. Representative photomicrographs show -Gal/control and 7B2-
transfected -TC6 cells. The adenovirus-induced overexpression of 7B2 is
accompanied by increased cellular glucagon levels (B). RNAi-mediated
knockdown of 7B2 was efficiently induced using 7B2-specific siRNA (C). Rep-
resentative photomicrographs show FITC-labeled scrambled siRNA control
(FITC/control) and 7B2-siRNA transfected -TC6 cells. Decrease of intracellu-
lar 7B2 is associatedwith a significant dropof intracellular glucagon levels (D).
Data represent n 3 wells/group, mean S.D. (error bars); one-way ANOVA;
**, p 0.01; ***, p 0.001.
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directly correlatedwith 7B2 expression levels (22); we therefore
decided to investigate this precursor system. Adenoviral infec-
tion of -TC6 cells with 7B2-encoding virus increased 7B2 lev-
els 2.5-fold (Fig. 5A). Immunoreactive glucagon also increased
by 50% (Fig. 5B), confirming that in -TC6 cells, increased 7B2
expression correlates directly with increased bioactive peptide
production. When 7B2 siRNA was added to -TC6 cells, 7B2
levels dropped by 62% (Fig. 5C); immunoreactive glucagon lev-
els also decreased by 50% (Fig. 5D). These results indicate that
in -TC6 cells, 7B2 levels are rate-limiting for glucagon
production.
In POMC-expressing -TC6 and Glucagon-expressing AtT-
20/PC2 Cells, Knockdown of 7B2 by siRNA Transfection Lowers
the Production of Glucagon but Does Not Affect POMC
Processing—The above results show that although POMC
processing is not altered by modulation of 7B2 expression in
AtT-20/PC2 cells, proglucagon processing is affected in -TC6
cells. To determine whether the 7B2-mediated effect on prog-
lucagon processing is cell type- or precursor-specific, we trans-
fected -TC6 cells (endogenously expressing proglucagon)
with plasmid DNA encoding POMC.We also transfected AtT-
20/PC2 cells (endogenously expressing POMC) with plasmid
DNA encoding proglucagon. This was followed by RNAi-me-
diated knockdown of 7B2 in both cell lines (Fig. 6).
7B2-dependent changes in the generation of proglucagon-
and POMC-derived peptides in -TC6 (Fig. 6A) and AtT-20/
PC2 (Fig. 6B) cells were analyzed by pulse-chase experiments
using [35S]methionine/cysteine followed by immunoprecipita-
tion. Fig. 6 (top panels) shows that labeled proglucagon (left)
and POMC (right) species in the two cell lines are present both
as the intact precursor and as smaller cleaved forms. Compar-
ison of the peak intensities of the various labeled glucagon
forms indicates that the ratio of cellular proglucagon to cleaved
products increased when 7B2 was knocked down, whereas at
the same time, levels of smaller proglucagon-derived peptides
decreased. A decrease in proglucagon-derived products (and an
increase in proglucagon) were also observed when pulse-chase
samples were analyzed using SDS-PAGE and phosphorimaging
following 7B2 knockdown (supplemental Fig. S3). In addition,
quantification of glucagon concentrations within the pulse-
chase samples by RIA showed that glucagon levels decreased by
50% versus controls when 7B2 was knocked down, in both
-TC6 and AtT-20/PC2 cells (Fig. 6, A and B, bottom panels).
By comparison, cleavage patterns of POMC were only
slightly altered in response to the RNAi-mediated decrease of
7B2 (Fig. 6, A and B, top panels). There was no significant
change in cellular levels of POMC and no discernable effect of
lowered 7B2 levels on the production of POMC-derived pep-
tides. This observation was confirmed by measuring cellular
-MSH concentrations using an -MSH-specific RIA in 7B2-
RNAi and control chase samples (Fig. 6, A and B, bottom
panels).
In summary, glucagon production was affected by 7B2
manipulation in both cell lines, whereas processing patterns of
POMC were only slightly altered. Thus, these results indicate
distinct precursor specificity for 7B2-mediated effects.
Furthermore, we tested whether the storage and secretion
patterns of active PC2 in-TC6 cells differ from those observed
in AtT-20/PC2 cells. This was accomplished by measuring
enzymatic activity of secreted and cellular PC2 following ade-
novirus-induced overexpression of 7B2. Fig. 7 shows that in
-TC6 cells, adenoviral overexpression of 7B2 decreased the
release of active PC2, in direct contrast to results obtained in
AtT-20/PC2 cells, where adenoviral infection increased the
amount of active PC2 secreted (Fig. 3B). At the same time, how-
ever, intracellular PC2 activity was increased (Fig. 7), possibly
accounting for the enhanced amounts of mature glucagon
observed in Fig. 5B.
Up-regulation of 7B2 inCongenic B62D-3 F2 cast/castMice Is
Accompanied by Increased Levels of Blood Glucagon and Glu-
cose Levels—Congenic B62D-3 F2 mice heterogeneous for cer-
tain alleles (known as “cast” alleles) within a specific domain of
chromosome 2 harboring the 7B2 locus have been demon-
strated to differentially express 7B2. Mice homozygous for the
cast alleles in this region express nearly 3 times more 7B2
mRNA and protein than mice with b6 alleles in this region,
whereas heterozygous mice are intermediate expressers (29).
FIGURE 6. RNAi-mediated knockdown of 7B2 in POMC-expressing -TC6 and proglucagon-expressing AtT-20/PC2 cells decreases the production of
cellular glucagon,whereas levels of POMCand its products areunaltered.-TC6 cellswere transfectedwith POMC, andAtT-20/PC2 cellswere transfected
with preproglucagon followed by knockdown of 7B2 with siRNA. Cells were pulse-labeled with [35S]Met/Cys and chased for the indicated time periods.
Immunoprecipitates of glucagon- and POMC-related products were size-separated by high performance gel permeation chromatography, and selected
fractions were subjected to quantification by scintillation counting (top panels). Additionally, glucagon- or -MSH-specific RIAs were utilized to quantify the
levels of cleavageproducts in thepulse/chase samples (bottompanels).Metabolic labeling showeddecreasedconversionofproglucagon into smaller cleavage
products when 7B2was knocked down in-TC6 (A, top left) and AtT-20/PC2 cells (B, top left). Quantification of cleaved glucagon levels in pulse-chase samples
by RIA revealeddecreased concentrations ofmature glucagon after treatmentwith 7B2 siRNA (bottom left panels). Cleavagepatterns of POMC inboth cell lines
were largely unaltered following 7B2 knockdown (top right panels); therewas also no difference in the production of-MSHwithin the samples as determined
byRIA (bottom right panels). Data representn2wells/group, eachmeasured in triplicate,meanS.D. (error bars); one-wayANOVA; **,p0.01; ***,p0.001.
T0, time point zero; T1, 1-h incubation; T2, 2-h incubation. PRO-GLU, proglucagon,GRPP-GLU, glicetin-related pancreatic polypeptide-glucagon fragment;GLU,
glucagon.
FIGURE 7. Decreased PC2 activity is secreted from -TC6 cells following
7B2 overexpression by adenoviral transduction, whereas cellular PC2
activity is increased. -TC6 Cells were infected for 24 h with control adeno-
virus or adenovirus encoding 7B2 for 24 h followed by incubation in Opti-
MEM for 18 h; conditioned medium and cell extracts were collected. Activity
of PC2 in the medium and in cell extracts was measured in the presence of
protease inhibitors and with and without the 7B2 C-terminal peptide to
assess specificity. Overexpression of 7B2was accompanied by decreased PC2
activity in themedium,whereas 7B2 overexpression increased the amount of
active PC2 within cells. Data represent n 3 wells/group, mean S.D.; one-
way ANOVA; **, p 0.01 (error bars).
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Quantification of mature glucagon in blood plasma samples by
RIA within these three genotypes revealed a significant 60%
increase in the high 7B2-expressing cast/castmice (p 0.008)
(Fig. 8A). Increased glucagon levels in cast/cast mice were
accompanied by increased blood glucose levels in 7B2 overex-
pressing mice (p 0.034) (Fig. 8B).
DISCUSSION
The small neuroendocrine protein 7B2, present in all neural
and endocrine tissues, is now known to be required for the
successful maturation of cellular proPC2 to an active form
(reviewed in Refs. 13 and 14).More recent work has shown that
7B2 acts to block the aggregation of proPC2 into unactivatable
forms (15). 7B2may subserve additional functions, because it is
present in cells lacking PC2 (32) and also circulates in blood (14,
21). In the intermediate lobe of the 7B2 null mouse pituitary,
the lack of 7B2 results in the absence of PC2 activity. This elim-
inates an important PC2-mediated step (4) in the processing of
proopiomelanocortin, the cleavage of intact adrenocortico-
tropic hormone 1–39 to adrenocorticotropic hormone 1–14,
the precursor of -MSH, and corticotropin-like intermediate
lobe peptide (18). In 7B2 nulls, adenovirally expressed 7B2
decreases the intermediate lobe content of intact adrenocorti-
cotropic hormone 1–39 and decreases adrenocorticotropic
hormone hypersecretion (21), supporting the idea that 7B2 lev-
els directly control adrenocorticotropic hormone processing in
this tissue. However, stable overexpression of 7B2 in AtT-20/
PC2 cells, a pituitary-derived cell line, did not result in
increased adrenocorticotropic hormone processing to -MSH,
indicating that the correlation between 7B2 and adrenocortico-
tropic hormone processing does not hold in all cell systems.
The goal of the present study was to elucidate the effects of 7B2
on precursor processing in several different neuroendocrine
systems.
Similar to results found in intact null animals (18), our stud-
ies show that 7B2 adenoviral infection of primary pituitary cells
obtained from 7B2 null mice results in elevated -MSH levels.
This indicates that 7B2 overexpression can also rescue proopi-
omelanocortin processing defects in primary tissue culture.
However, the finding of enhanced precursor processing did not
extend to the PC2-overexpressing cell line, AtT-20/PC2. The
major effect we consistently observed as a consequence of
infection of this cell line with 7B2-encoding adenovirus was
greatly increased secretion of PC2 activity. Increased secretion
of active PC2 caused by 7B2 introduction was also observed by
Seidel et al. (11) in SK-N-MCIX cells, the only neuroendocrine
cell line that does not endogenously express 7B2; peptide pre-
cursor processing was not examined in this study. However, in
AtT-20/PC2 cells, increased release of active enzyme was not
accompanied by increased precursor processing. Similar results
were observed in RinPE cells, in which 7B2 also did not appear
to represent a limiting factor for Peptide B conversion to Met-
enkephalin-Arg-Phe, a known PC2-mediated event (24). We
speculate that inAtT-20 andRin cells, the additional active PC2
generated by 7B2 overexpression may not reach the secretory
granule compartment (where its adrenocorticotropic hormone
substrate is concentrated) but is instead secreted constitutively.
We also considered the possibility that the time required for
complete processing of a given PC2 substrate is reached more
quickly in some cell types (such as -TC6) and for some sub-
strates (e.g. proglucagon) than in other cells and for other sub-
strates. The fact that adenoviral overexpression of 7B2 in
-TC6 cells resulted in increased processing of proglucagon
accompanied by decreased secretion of active enzyme (rather
than the increased secretion observed in AtT-20 cells) strongly
implies that 7B2-mediated targeting of PC2 differs between
various cell lines. This suggests that 7B2 overexpression can
only result in increased precursor cleavage when the increased
FIGURE 8. Circulating glucagon and glucose levels are increased in 7B2-overexpressing B62D-3 F2 cast/castmice. Blood plasma glucagon and glucose
levels of congenic B62D-3 F2mice weremeasured by glucagon-specific RIA and with a handheld glucosemeter in three genotypes with varying levels of 7B2
expression.With regard to levels of 7B2, b6/b6mice represent low 7B2 expressers (n 8); b6/castmice represent intermediate expressers (n 3); and cast/cast
mice represent high expressers (n 8) (mean S.E. (error bars); one-way ANOVA; *, p 0.05; **, p 0.01).
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active PC2 is actually targeted to secretory granules. However,
we also found that various prohormone substrates can be dif-
ferentially affected by 7B2 manipulation. Our proglucagon and
proopiomelanocortin processing experiments in AtT-20 cells
show that reduction of 7B2 levels by antisense lowered PC2-
mediated proglucagon processing while leaving proopiomela-
nocortin processing entirely intact. These results agree with
previous proopiomelanocortin processing results in 7B2-over-
expressing AtT-20 cells (31) and results obtained in vivo, where
the increased 7B2 level present in cast/cast mice has no effect
on circulating or pituitary -MSH (29). Our present observa-
tion of increased glucagon in cast/cast mice also supports the
finding by Schmidt et al. (22) that circulating glucagon levels
correlate positively with differing pancreatic 7B2 expression in
various mouse strains. Thus, manipulation of 7B2 levels
appears to more profoundly affect processing of proglucagon
than other precursors. One possible explanation for this effect
is a relatively enhanced susceptibility of the proglucagon pre-
cursor and/or its glucagon-containing intermediates to PC2-
mediated cleavage. Indeed, our pulse-chase results show that
not only glucagon but also proglucagon is affected by 7B2 anti-
sense introduction. Preliminary experiments using purified
peptides also show that the glucagon precursor oxyntomodulin
is more easily cleaved by PC2 than is the -MSH precursor
adrenocorticotropic hormone. It will be interesting in future
work to compare the relative susceptibility of other pancreatic
PC2-cleaved precursors, such as islet amyloid polypeptide (33)
and proinsulin, to manipulation of 7B2 levels to determine
whether the profound effect of 7B2 on proglucagon processing
is unique. If so, this might bode well for the development of
therapeutic PC2 inhibitors targeted toward the reduction of
pancreatic and circulating glucagon in diabetes.
In conclusion, our data indicate that 7B2 expression repre-
sents an important factor in the control of peptide processing.
These results are of interest in light of the fact that differences
in the 7B2 promoter have been shown to affect its expression
both in mice (22, 29) and in humans (34). Genetic polymor-
phisms in the 7B2 promoter have been associated with glucose
intolerance (35), supporting the physiological relevance of
alterations in 7B2 expression. Because large reservoirs of
proPC2 are stored in the endoplasmic reticulum of many PC2-
expressing cells (36, 37), dynamic regulation of 7B2 levels could
potentially result in a relatively rapid and selective increase in
cellular production of bioactive peptide.
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